Automated Insulin Delivery and Monitoring System Approved by FDA for Use in Younger Pediatric Patients – Drug for nerve pain boosts high for opioid abusers.

16511-pharmacy-board-standard-041216Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Automated Insulin Delivery and Monitoring System Approved by FDA for Use in Younger Pediatric Patients – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have expanded the approval of Medtronic’s MiniMed 670G hybrid closed looped system to include individuals aged 7 to 13 with Type 1 diabetes. The FDA originally approved this diabetes management device, which is intended to automatically monitor glucose, and to provide appropriate basal insulin doses with little or no input from the user, in September 2017 for use in patients 14 years of age and older with Type 1 diabetes.

In a statement, FDA Commissioner Scott Gottlieb, MD, said management of Type 1 diabetes can be stressful for patients and their caregivers, and especially when the patients are young children. “Caregivers and families of young patients with diabetes face unique challenges in managing this disease, in particular the round-the-clock glucose monitoring that can be disruptive to people’s lives.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.